ES2174007T3 - Derivados de biotina. - Google Patents

Derivados de biotina.

Info

Publication number
ES2174007T3
ES2174007T3 ES96114454T ES96114454T ES2174007T3 ES 2174007 T3 ES2174007 T3 ES 2174007T3 ES 96114454 T ES96114454 T ES 96114454T ES 96114454 T ES96114454 T ES 96114454T ES 2174007 T3 ES2174007 T3 ES 2174007T3
Authority
ES
Spain
Prior art keywords
sub
biotine
diseases
sup
asp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96114454T
Other languages
English (en)
Inventor
Alfred Dr Jonczyk
Simon Dr Goodman
Beate Dr Diefenbach
Horst Prof Kessler
Dirk Finsinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Application granted granted Critical
Publication of ES2174007T3 publication Critical patent/ES2174007T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)

Abstract

COMPUESTOS DE BIOTINA DE FORMULA I EN DONDE Q FALTA O ES -NH-(CH{SUB,2}){SUB,N}-CO- O -NH-(CH{SUB,2}){SUB,N}NH-, Y R{SUP,1} ES X-ARG-GLY-ASP-Y, A-CYS-(R{SUP,2})-B-U O CICLO-(ARGGLY-ASP-Z), ESTANDO Z UNIDA A LA CADENA LATERAL POR Q, O SI Q FALTA, UNIDA A LA BIOTINA, Y A, B, U, X, Y, Z Y N TIENEN LOS SIGNIFICADOS DADOS EN LA REIVINDICACION 1, ASI COMO SUS SALES, SE PUEDEN UTILIZAR COMO INHIBIDORES DE LA INTEGRINA, EN PARTICULAR PARA LA PROFILAXIS Y EL TRATAMIENTO DE ENFERMEDADES DE LA CIRCULACION, TROMBOSIS, INFARTO, ENFERMEDADES CORONARIAS, ARTERIOESCLEROSIS, ENFERMEDADES ANGIOGENICAS Y EN LA TERAPIA TUMORAL.
ES96114454T 1995-09-14 1996-09-10 Derivados de biotina. Expired - Lifetime ES2174007T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19534016A DE19534016A1 (de) 1995-09-14 1995-09-14 Biotinderivate

Publications (1)

Publication Number Publication Date
ES2174007T3 true ES2174007T3 (es) 2002-11-01

Family

ID=7772112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96114454T Expired - Lifetime ES2174007T3 (es) 1995-09-14 1996-09-10 Derivados de biotina.

Country Status (23)

Country Link
EP (1) EP0771818B1 (es)
JP (1) JP4127325B2 (es)
KR (1) KR970015597A (es)
CN (1) CN1168738C (es)
AT (1) ATE215558T1 (es)
AU (1) AU719307B2 (es)
BR (1) BR9603741A (es)
CA (1) CA2185394C (es)
CZ (1) CZ291506B6 (es)
DE (2) DE19534016A1 (es)
DK (1) DK0771818T3 (es)
ES (1) ES2174007T3 (es)
HU (1) HUP9602223A3 (es)
MX (1) MX9604019A (es)
NO (1) NO314694B1 (es)
PL (1) PL316069A1 (es)
PT (1) PT771818E (es)
RU (1) RU2171807C2 (es)
SI (1) SI0771818T1 (es)
SK (1) SK283129B6 (es)
TW (1) TW517063B (es)
UA (1) UA41981C2 (es)
ZA (1) ZA967765B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20012320A3 (cs) 1998-12-23 2002-10-16 G. D. Searle & Co. Léčivo s obsahem inhibitoru cyklooxygenázy-2 a jednoho nebo více antineoplastických činidel pro kombinační terapii při léčení neoplasie
US20010053766A1 (en) * 2000-02-11 2001-12-20 Janardan Kumar Method of treating disorders of the eye
KR100778633B1 (ko) * 2007-04-13 2007-11-28 성균관대학교산학협력단 비오틴과 비오틴-폴리에틸렌글리콜이 접합된 ｇｌｐ-1유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
RU2555357C2 (ru) * 2008-04-08 2015-07-10 Мерк Патент Гмбх Композиции, содержащие циклические пептиды, и способы их применения
CN108956790A (zh) * 2017-05-18 2018-12-07 中国人民解放军第二军医大学第二附属医院 一组氨基酸标志物在急性肾损伤诊断试剂盒中的应用
CN113827591B (zh) * 2021-11-09 2023-06-09 上海市肺科医院 生物素在制备治疗脓毒症药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5315076B2 (es) * 1973-09-27 1978-05-22
JP2945680B2 (ja) * 1988-09-09 1999-09-06 旭硝子株式会社 ペプチド誘導体およびその用途
US5087561A (en) * 1990-06-28 1992-02-11 Merck & Co., Inc. Humoral hypercalcemic factor antagonists modified at position 13 by biotin
DE4310643A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
US5462939A (en) * 1993-05-07 1995-10-31 Sterling Winthrop Inc. Peptidic ketones as interleukin-1β-converting enzyme inhibitors
DE4336758A1 (de) * 1993-10-28 1995-05-04 Merck Patent Gmbh Lineare Adhäsionsinhibitoren

Also Published As

Publication number Publication date
NO963851L (no) 1997-03-17
CZ262996A3 (cs) 1998-02-18
HUP9602223A2 (en) 1997-06-30
HUP9602223A3 (en) 1998-03-02
UA41981C2 (uk) 2001-10-15
NO314694B1 (no) 2003-05-05
EP0771818A2 (de) 1997-05-07
SK283129B6 (sk) 2003-02-04
CN1168738C (zh) 2004-09-29
DK0771818T3 (da) 2002-07-29
CA2185394A1 (en) 1997-03-15
TW517063B (en) 2003-01-11
AU719307B2 (en) 2000-05-04
BR9603741A (pt) 1998-06-02
JPH09124692A (ja) 1997-05-13
ATE215558T1 (de) 2002-04-15
MX9604019A (es) 1997-03-29
EP0771818A3 (de) 1997-07-02
PT771818E (pt) 2002-09-30
KR970015597A (ko) 1997-04-28
DE19534016A1 (de) 1997-03-20
RU2171807C2 (ru) 2001-08-10
HU9602223D0 (en) 1996-10-28
NO963851D0 (no) 1996-09-13
ZA967765B (en) 1997-03-26
CA2185394C (en) 2007-05-01
SI0771818T1 (en) 2002-10-31
JP4127325B2 (ja) 2008-07-30
CN1153784A (zh) 1997-07-09
AU6551896A (en) 1997-03-20
SK115696A3 (en) 1997-05-07
PL316069A1 (en) 1997-03-17
DE59608995D1 (de) 2002-05-08
CZ291506B6 (cs) 2003-03-12
EP0771818B1 (de) 2002-04-03

Similar Documents

Publication Publication Date Title
ES2183332T3 (es) Aminoacidos biciclicos aromaticos.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
CO5050288A1 (es) Derivados de 1,4-oxazolina y de 1,3-tiazolina, procedimiento y su utilizacion como agentes plaguicidas
DE69941800D1 (de) Salze von Liponsaürederivaten und deren Verwendung bei der Behandlung von Krankheiten
ES2163916T3 (es) Profarmacos de inhibidores de trombina.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
DK130387D0 (da) Transglutaminase inhibitorer
ES2120993T3 (es) Agentes antitromboticos.
DE68925505D1 (de) Zusammensetzungen zum Erreichen eines Lasereffektes und Methoden zu deren Gebrauch
TR199901949T2 (xx) Lemfositik t�m�rler i�in �areler.
UY29979A1 (es) Derivados espirociclicos
ES2174007T3 (es) Derivados de biotina.
CO4930277A1 (es) Nuevos compuestos
DE69500511D1 (de) Phosphatdiester zur Behandlung von proliferativen Erkrankungen der Epidermis
ATE216892T1 (de) Inhibitor von nebenwirkungen zur krebstherapy
ES2164765T3 (es) Heterociclilbenzonitrilos.
ES2125537T3 (es) Arilbenzoilguanidinas.
BR9810394A (pt) Azapeptìdeos cìclicos
MX9304626A (es) Derivados heterociclicos utiles en el tratamiento de enfermedades cardiovasculares.
DE60144383D1 (de) Methoden zur verminderung oder verhinderung von schmerzen mit spicamycin-derivaten
DE69002328D1 (de) Geminale bisphosphonsaeuren und deren derivate als antiarthritische mittel.
TR200201251T2 (tr) Omega zinciri tadil edilmiş 15-hidroksieikosatetraenoik asit türevleri ve bunların göz kurumasının iyileştirilmesi için kullanım yöntemleri
ATE120447T1 (de) Polyamin-derivate als antineoplastische mittel.
NO944093L (no) Lineære adhesjonsinhibitorer
CO5021190A1 (es) Agentes terapeuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 771818

Country of ref document: ES